Tower Research Capital LLC TRC Has $55,000 Stock Holdings in Viking Therapeutics Inc (NASDAQ:VKTX)

Share on StockTwits

Tower Research Capital LLC TRC grew its holdings in Viking Therapeutics Inc (NASDAQ:VKTX) by 3,261.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,001 shares of the biotechnology company’s stock after purchasing an additional 7,763 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Viking Therapeutics were worth $55,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in VKTX. Capital Investment Advisory Services LLC lifted its stake in shares of Viking Therapeutics by 126.5% in the 2nd quarter. Capital Investment Advisory Services LLC now owns 3,850 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 2,150 shares during the period. Quantamental Technologies LLC acquired a new position in shares of Viking Therapeutics in the 2nd quarter valued at about $50,000. Wedbush Securities Inc. acquired a new position in shares of Viking Therapeutics in the 2nd quarter valued at about $97,000. Hayden Royal LLC acquired a new position in shares of Viking Therapeutics in the 2nd quarter valued at about $111,000. Finally, Alpine Group USVI LLC acquired a new position in shares of Viking Therapeutics in the 3rd quarter valued at about $172,000. 56.45% of the stock is currently owned by institutional investors.

VKTX stock opened at $7.32 on Monday. The stock’s 50 day simple moving average is $7.07 and its 200 day simple moving average is $7.47. Viking Therapeutics Inc has a fifty-two week low of $6.15 and a fifty-two week high of $11.66. The company has a market cap of $528.97 million, a P/E ratio of -18.30 and a beta of 2.30.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. Equities analysts predict that Viking Therapeutics Inc will post -0.39 EPS for the current year.

A number of research analysts recently weighed in on the company. ValuEngine raised Viking Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. BidaskClub downgraded Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 6th. B. Riley assumed coverage on Viking Therapeutics in a research note on Thursday, November 21st. They set a “buy” rating and a $16.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price target on shares of Viking Therapeutics in a research note on Tuesday, November 5th. Finally, Maxim Group reaffirmed a “buy” rating and set a $14.00 price target on shares of Viking Therapeutics in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $18.76.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

See Also: What is the CAC 40 Index

Institutional Ownership by Quarter for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.